查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1573116

癌症生技药品市场：依治疗药物、细胞治疗药物、癌症疫苗分类 - 全球预测 2025-2030

Cancer Biologics Market by Therapies, Cell Therapies, Cancer Vaccines - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年癌症生技药品市场规模为967.1亿美元，预计2024年将达到1,020.5亿美元，复合年增长率为6.30%，2030年将达到1,483.5亿美元。

癌症生技药品是製药业中快速发展的一个领域，专注于使用比传统化疗更精确地针对癌细胞的生物物质和系统。这些生物製药包括单株抗体、生长因子抑制剂、基因疗法和个人化疫苗。这种需求源于对标靶治疗的需求，以最大限度地减少对健康细胞的附带损害、改善患者的治疗效果并减少副作用。癌症生技药品的应用范围从治疗到诊断再到预后，最终用途包括医院、诊所和专门的癌症治疗中心。

主要市场统计
基准年[2023] 967.1亿美元
预测年份 [2024] 1020.5亿美元
预测年份 [2030] 1483.5亿美元
复合年增长率（%） 6.30%

癌症生技药品市场是由癌症发生率上升、生物技术进步以及研发投资快速增加所推动的。关键的成长要素包括扩大新兴国家的医疗保健覆盖范围、对生物製药的监管支持以及意识提升。一个潜在的机会在于开发具有成本效益的生物相似药来取代品牌生技药品。为了抓住这个机会，公司必须投资强有力的临床试验并有效地通过生物相似药核准途径。此外，利用人工智慧和机器学习进行生物标记发现可以促进个人化医疗的方法，提供显着的成长前景。

然而，该市场面临一些挑战，包括高昂的开发成本、严格的监管要求以及製造生物製药的复杂性。智慧财产权和市场竞争也是主要障碍，这可能导致限制可及性的高定价策略。为了实现永续成长，创新者应专注于提高製造效率和扩大合作研究伙伴关係。

有前景的创新领域包括利用 CRISPR 技术进行基因编辑探索新的治疗标靶，以及研究微生物组在癌症治疗中的作用。了解竞争格局和市场的本质（其特点是快速发展和激烈竞争）使公司能够制定有效的策略并进行创新。透过应对挑战和利用新技术进步，公司可以利用癌症生技药品带来的快速成长机会。

市场动态：揭示快速发展的癌症生技药品市场的关键市场洞察

供需的动态交互作用正在改变癌症生技药品市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助企业了解消费行为及其对製造业的影响。

  • 市场驱动因素
    • 加强关注早期癌症检测和个人化治疗
    • 生物製药製造的技术进步提高了成本效率和生产力
    • 学术机构与生物製药公司加强癌症药物创新合作
    • 新兴市场医疗保健基础设施的扩大和生技药品的获取增加有助于市场成长
  • 市场限制因素
    • 复杂的供应链和冷藏保管物流带来了配送挑战并增加了成本
    • 报销和承保范围限制限制了患者获得昂贵的生技药品治疗
  • 市场机会
    • 免疫疗法技术的进步提高了治疗效果和市场渗透率
    • 透过整合人工智慧和机器学习对癌症生技药品进行预测分析
    • 由于诊断能力的提高，癌症生技药品在新兴市场的扩张
  • 市场挑战
    • 由于生技药品复杂的监管核准流程导致市场准入延迟
    • 获得可靠的临床试验资料来证明生技药品的有效性和安全性是一项挑战

波特五力：驾驭癌症生技药品市场的策略工具

波特的五力架构是了解癌症生技药品市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解癌症生技药品市场的外部影响

外部宏观环境因素在塑造生技药品市场的表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解生技药品市场的竞争格局

癌症生技药品市场的详细市场占有率分析可以对供应商绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵生技药品市场供应商的绩效评估

FPNV定位矩阵是评估生技药品市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，规划生技药品市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，癌症生技药品市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 加强关注早期癌症检测和个人化治疗方案
      • 生物製药製造的技术进步提高了成本效率和生产力。
      • 加强学术机构与生物製药公司合作创新癌症治疗药物
      • 扩大新兴市场的医疗基础设施和生技药品的取得有助于市场成长
    • 抑制因素
      • 复杂的供应链和冷藏物流带来了配送挑战并增加了成本
      • 报销和保险范围的限制使患者无法接受昂贵的生物製药治疗。
    • 机会
      • 免疫疗法技术的进步提高了治疗效果和市场渗透率
      • 将人工智慧和机器学习整合到生技药品中进行预测分析
      • 由于诊断能力的提高，癌症生技药品在新兴市场的扩张
    • 任务
      • 癌症生技药品复杂的监管核准流程延迟了市场进入
      • 获得可靠的临床试验资料以证明生技药品的有效性和安全性面临的挑战
  • 市场区隔分析
  • 波特五力分析
  • PESTLE分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章癌症生技药品市场治疗

  • 双特异性单株抗体
  • 结合单株抗体
    • 化学标记抗体
    • 放射性标记抗体
  • 单株抗体

第七章癌症生技药品市场细胞疗法

  • 树突细胞疗法
  • 自然杀手细胞疗法
  • T细胞疗法

第八章癌症生技药品市场癌症疫苗

  • 癌症预防疫苗
  • 治疗性癌症疫苗

第九章美洲生技药品市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太癌症生技药品市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章欧洲、中东和非洲的癌症生技药品市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议
Product Code: MRR-1A1A064C014D

The Cancer Biologics Market was valued at USD 96.71 billion in 2023, expected to reach USD 102.05 billion in 2024, and is projected to grow at a CAGR of 6.30%, to USD 148.35 billion by 2030.

Cancer biologics represent a rapidly evolving segment within the pharmaceutical industry, focused on using biological substances or systems to target cancer cells more precisely than traditional chemotherapies. These biologics include monoclonal antibodies, growth factor inhibitors, gene therapy, and personalized vaccines. Their necessity stems from the need for targeted therapeutics that minimize collateral damage to healthy cells, enhancing patient outcomes and reducing adverse effects. The application of cancer biologics spans from treatment to diagnostics and prognostics, with end-use scope including hospitals, clinics, and specialized cancer treatment centers.

KEY MARKET STATISTICS
Base Year [2023] USD 96.71 billion
Estimated Year [2024] USD 102.05 billion
Forecast Year [2030] USD 148.35 billion
CAGR (%) 6.30%

The market for cancer biologics is being driven by increasing cancer prevalence, advancements in biotechnology, and a surge in R&D investments. Key growth factors include expanded healthcare access in emerging economies, regulatory support for biological drugs, and increasing patient awareness. One potential opportunity lies in the development of biosimilars, offering cost-effective alternatives to branded biologics. To seize this opportunity, companies should invest in robust clinical trials and navigate the biosimilar approval pathways effectively. Additionally, leveraging AI and machine learning for biomarker discovery can expedite personalized medicine approaches, offering significant growth prospects.

However, several challenges confront the market, including high development costs, stringent regulatory requirements, and the complexity of manufacturing biological products. Intellectual property and market competition also pose substantial hurdles, potentially leading to high pricing strategies that limit accessibility. For sustained growth, innovators should focus on improving manufacturing efficiencies and expanding collaborative research partnerships.

Promising areas of innovation include the exploration of novel therapeutic targets using CRISPR technology for gene editing and investigating the microbiome's role in cancer therapy. Understanding the competitive landscape and the nature of the market, which is characterized by rapid advancements and high competition, can position companies to effectively strategize and innovate. By addressing the challenges and leveraging emerging technological advancements, businesses can capitalize on the burgeoning opportunities presented by cancer biologics.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cancer Biologics Market

The Cancer Biologics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising number of initiatives focused on early cancer detection and personalized treatment options
    • Technological advancements in biologic drug manufacturing leading to cost efficiency and higher production rates
    • Increasing collaborations between academic institutions and biopharmaceutical companies for cancer drug innovation
    • Expansion of healthcare infrastructure and access to biologics in emerging markets contributing to market growth
  • Market Restraints
    • Complex supply chain and cold storage logistics create challenges in distribution and increase costs
    • Reimbursement and insurance coverage restrictions limit patient access to expensive biologics treatments
  • Market Opportunities
    • Advancement in immunotherapy techniques enhancing treatment effectiveness and market penetration
    • Integrating artificial intelligence and machine learning in cancer biologics for predictive analytics
    • Expansion of cancer biologics in emerging markets due to increased diagnostic capabilities
  • Market Challenges
    • Navigating complex regulatory approval processes for cancer biologics causing delays in market entry
    • Challenges in obtaining robust clinical trial data for proving the efficacy and safety of cancer biologics

Porter's Five Forces: A Strategic Tool for Navigating the Cancer Biologics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cancer Biologics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cancer Biologics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cancer Biologics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cancer Biologics Market

A detailed market share analysis in the Cancer Biologics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cancer Biologics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cancer Biologics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Cancer Biologics Market

A strategic analysis of the Cancer Biologics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Cancer Biologics Market, highlighting leading vendors and their innovative profiles. These include AbbVie, Amgen, AstraZeneca, Bayer, Biogen, Bristol-Myers Squibb, Celgene, Eli Lilly and Company, Gilead Sciences, GlaxoSmithKline, Incyte Corporation, Johnson & Johnson, Merck & Co., Novartis, Pfizer, Regeneron Pharmaceuticals, Roche, Sanofi, Seattle Genetics, and Takeda Pharmaceutical.

Market Segmentation & Coverage

This research report categorizes the Cancer Biologics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Therapies, market is studied across Bispecific Monoclonal Antibodies, Conjugated Monoclonal Antibodies, and Monoclonal Antibodies. The Conjugated Monoclonal Antibodies is further studied across Chemolabelled Antibodies and Radiolabelled Antibodies.
  • Based on Cell Therapies, market is studied across Dendritic Cell Therapy, Natural Killer Cell Therapy, and T-Cell Therapy.
  • Based on Cancer Vaccines, market is studied across Preventive Cancer Vaccines and Therapeutic Cancer Vaccines.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising number of initiatives focused on early cancer detection and personalized treatment options
      • 5.1.1.2. Technological advancements in biologic drug manufacturing leading to cost efficiency and higher production rates
      • 5.1.1.3. Increasing collaborations between academic institutions and biopharmaceutical companies for cancer drug innovation
      • 5.1.1.4. Expansion of healthcare infrastructure and access to biologics in emerging markets contributing to market growth
    • 5.1.2. Restraints
      • 5.1.2.1. Complex supply chain and cold storage logistics create challenges in distribution and increase costs
      • 5.1.2.2. Reimbursement and insurance coverage restrictions limit patient access to expensive biologics treatments
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancement in immunotherapy techniques enhancing treatment effectiveness and market penetration
      • 5.1.3.2. Integrating artificial intelligence and machine learning in cancer biologics for predictive analytics
      • 5.1.3.3. Expansion of cancer biologics in emerging markets due to increased diagnostic capabilities
    • 5.1.4. Challenges
      • 5.1.4.1. Navigating complex regulatory approval processes for cancer biologics causing delays in market entry
      • 5.1.4.2. Challenges in obtaining robust clinical trial data for proving the efficacy and safety of cancer biologics
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Cancer Biologics Market, by Therapies

  • 6.1. Introduction
  • 6.2. Bispecific Monoclonal Antibodies
  • 6.3. Conjugated Monoclonal Antibodies
    • 6.3.1. Chemolabelled Antibodies
    • 6.3.2. Radiolabelled Antibodies
  • 6.4. Monoclonal Antibodies

7. Cancer Biologics Market, by Cell Therapies

  • 7.1. Introduction
  • 7.2. Dendritic Cell Therapy
  • 7.3. Natural Killer Cell Therapy
  • 7.4. T-Cell Therapy

8. Cancer Biologics Market, by Cancer Vaccines

  • 8.1. Introduction
  • 8.2. Preventive Cancer Vaccines
  • 8.3. Therapeutic Cancer Vaccines

9. Americas Cancer Biologics Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Cancer Biologics Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Cancer Biologics Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie
  • 2. Amgen
  • 3. AstraZeneca
  • 4. Bayer
  • 5. Biogen
  • 6. Bristol-Myers Squibb
  • 7. Celgene
  • 8. Eli Lilly and Company
  • 9. Gilead Sciences
  • 10. GlaxoSmithKline
  • 11. Incyte Corporation
  • 12. Johnson & Johnson
  • 13. Merck & Co.
  • 14. Novartis
  • 15. Pfizer
  • 16. Regeneron Pharmaceuticals
  • 17. Roche
  • 18. Sanofi
  • 19. Seattle Genetics
  • 20. Takeda Pharmaceutical

LIST OF FIGURES

  • FIGURE 1. CANCER BIOLOGICS MARKET RESEARCH PROCESS
  • FIGURE 2. CANCER BIOLOGICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CANCER BIOLOGICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY THERAPIES, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY THERAPIES, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY CANCER VACCINES, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY CANCER VACCINES, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS CANCER BIOLOGICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS CANCER BIOLOGICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES CANCER BIOLOGICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES CANCER BIOLOGICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC CANCER BIOLOGICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC CANCER BIOLOGICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. CANCER BIOLOGICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. CANCER BIOLOGICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CANCER BIOLOGICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CANCER BIOLOGICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CANCER BIOLOGICS MARKET DYNAMICS
  • TABLE 7. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY BISPECIFIC MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY CONJUGATED MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY CHEMOLABELLED ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY RADIOLABELLED ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY CONJUGATED MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY DENDRITIC CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY NATURAL KILLER CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY T-CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY PREVENTIVE CANCER VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL CANCER BIOLOGICS MARKET SIZE, BY THERAPEUTIC CANCER VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS CANCER BIOLOGICS MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS CANCER BIOLOGICS MARKET SIZE, BY CONJUGATED MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS CANCER BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS CANCER BIOLOGICS MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS CANCER BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA CANCER BIOLOGICS MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA CANCER BIOLOGICS MARKET SIZE, BY CONJUGATED MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA CANCER BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA CANCER BIOLOGICS MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL CANCER BIOLOGICS MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL CANCER BIOLOGICS MARKET SIZE, BY CONJUGATED MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL CANCER BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL CANCER BIOLOGICS MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA CANCER BIOLOGICS MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA CANCER BIOLOGICS MARKET SIZE, BY CONJUGATED MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA CANCER BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA CANCER BIOLOGICS MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
  • TABLE 38. MEXICO CANCER BIOLOGICS MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO CANCER BIOLOGICS MARKET SIZE, BY CONJUGATED MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO CANCER BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO CANCER BIOLOGICS MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
  • TABLE 42. UNITED STATES CANCER BIOLOGICS MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES CANCER BIOLOGICS MARKET SIZE, BY CONJUGATED MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES CANCER BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES CANCER BIOLOGICS MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES CANCER BIOLOGICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 47. ASIA-PACIFIC CANCER BIOLOGICS MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC CANCER BIOLOGICS MARKET SIZE, BY CONJUGATED MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC CANCER BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC CANCER BIOLOGICS MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC CANCER BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 52. AUSTRALIA CANCER BIOLOGICS MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA CANCER BIOLOGICS MARKET SIZE, BY CONJUGATED MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA CANCER BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA CANCER BIOLOGICS MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
  • TABLE 56. CHINA CANCER BIOLOGICS MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA CANCER BIOLOGICS MARKET SIZE, BY CONJUGATED MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA CANCER BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA CANCER BIOLOGICS MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
  • TABLE 60. INDIA CANCER BIOLOGICS MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA CANCER BIOLOGICS MARKET SIZE, BY CONJUGATED MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA CANCER BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA CANCER BIOLOGICS MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
  • TABLE 64. INDONESIA CANCER BIOLOGICS MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA CANCER BIOLOGICS MARKET SIZE, BY CONJUGATED MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA CANCER BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA CANCER BIOLOGICS MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
  • TABLE 68. JAPAN CANCER BIOLOGICS MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN CANCER BIOLOGICS MARKET SIZE, BY CONJUGATED MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN CANCER BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN CANCER BIOLOGICS MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
  • TABLE 72. MALAYSIA CANCER BIOLOGICS MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA CANCER BIOLOGICS MARKET SIZE, BY CONJUGATED MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA CANCER BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA CANCER BIOLOGICS MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
  • TABLE 76. PHILIPPINES CANCER BIOLOGICS MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES CANCER BIOLOGICS MARKET SIZE, BY CONJUGATED MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES CANCER BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES CANCER BIOLOGICS MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
  • TABLE 80. SINGAPORE CANCER BIOLOGICS MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE CANCER BIOLOGICS MARKET SIZE, BY CONJUGATED MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE CANCER BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE CANCER BIOLOGICS MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
  • TABLE 84. SOUTH KOREA CANCER BIOLOGICS MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA CANCER BIOLOGICS MARKET SIZE, BY CONJUGATED MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA CANCER BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA CANCER BIOLOGICS MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
  • TABLE 88. TAIWAN CANCER BIOLOGICS MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN CANCER BIOLOGICS MARKET SIZE, BY CONJUGATED MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN CANCER BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN CANCER BIOLOGICS MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
  • TABLE 92. THAILAND CANCER BIOLOGICS MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND CANCER BIOLOGICS MARKET SIZE, BY CONJUGATED MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND CANCER BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND CANCER BIOLOGICS MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
  • TABLE 96. VIETNAM CANCER BIOLOGICS MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM CANCER BIOLOGICS MARKET SIZE, BY CONJUGATED MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM CANCER BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM CANCER BIOLOGICS MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICS MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICS MARKET SIZE, BY CONJUGATED MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICS MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 105. DENMARK CANCER BIOLOGICS MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK CANCER BIOLOGICS MARKET SIZE, BY CONJUGATED MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK CANCER BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK CANCER BIOLOGICS MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
  • TABLE 109. EGYPT CANCER BIOLOGICS MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT CANCER BIOLOGICS MARKET SIZE, BY CONJUGATED MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT CANCER BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT CANCER BIOLOGICS MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
  • TABLE 113. FINLAND CANCER BIOLOGICS MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND CANCER BIOLOGICS MARKET SIZE, BY CONJUGATED MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND CANCER BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND CANCER BIOLOGICS MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
  • TABLE 117. FRANCE CANCER BIOLOGICS MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE CANCER BIOLOGICS MARKET SIZE, BY CONJUGATED MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE CANCER BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE CANCER BIOLOGICS MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
  • TABLE 121. GERMANY CANCER BIOLOGICS MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY CANCER BIOLOGICS MARKET SIZE, BY CONJUGATED MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY CANCER BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY CANCER BIOLOGICS MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
  • TABLE 125. ISRAEL CANCER BIOLOGICS MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL CANCER BIOLOGICS MARKET SIZE, BY CONJUGATED MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL CANCER BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL CANCER BIOLOGICS MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
  • TABLE 129. ITALY CANCER BIOLOGICS MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY CANCER BIOLOGICS MARKET SIZE, BY CONJUGATED MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY CANCER BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY CANCER BIOLOGICS MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
  • TABLE 133. NETHERLANDS CANCER BIOLOGICS MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS CANCER BIOLOGICS MARKET SIZE, BY CONJUGATED MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS CANCER BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS CANCER BIOLOGICS MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
  • TABLE 137. NIGERIA CANCER BIOLOGICS MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA CANCER BIOLOGICS MARKET SIZE, BY CONJUGATED MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA CANCER BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA CANCER BIOLOGICS MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
  • TABLE 141. NORWAY CANCER BIOLOGICS MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY CANCER BIOLOGICS MARKET SIZE, BY CONJUGATED MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY CANCER BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY CANCER BIOLOGICS MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
  • TABLE 145. POLAND CANCER BIOLOGICS MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND CANCER BIOLOGICS MARKET SIZE, BY CONJUGATED MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND CANCER BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND CANCER BIOLOGICS MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
  • TABLE 149. QATAR CANCER BIOLOGICS MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR CANCER BIOLOGICS MARKET SIZE, BY CONJUGATED MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR CANCER BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR CANCER BIOLOGICS MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
  • TABLE 153. RUSSIA CANCER BIOLOGICS MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA CANCER BIOLOGICS MARKET SIZE, BY CONJUGATED MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA CANCER BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA CANCER BIOLOGICS MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
  • TABLE 157. SAUDI ARABIA CANCER BIOLOGICS MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA CANCER BIOLOGICS MARKET SIZE, BY CONJUGATED MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA CANCER BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA CANCER BIOLOGICS MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
  • TABLE 161. SOUTH AFRICA CANCER BIOLOGICS MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA CANCER BIOLOGICS MARKET SIZE, BY CONJUGATED MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA CANCER BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA CANCER BIOLOGICS MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
  • TABLE 165. SPAIN CANCER BIOLOGICS MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN CANCER BIOLOGICS MARKET SIZE, BY CONJUGATED MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN CANCER BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN CANCER BIOLOGICS MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
  • TABLE 169. SWEDEN CANCER BIOLOGICS MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN CANCER BIOLOGICS MARKET SIZE, BY CONJUGATED MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN CANCER BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN CANCER BIOLOGICS MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
  • TABLE 173. SWITZERLAND CANCER BIOLOGICS MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND CANCER BIOLOGICS MARKET SIZE, BY CONJUGATED MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND CANCER BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND CANCER BIOLOGICS MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
  • TABLE 177. TURKEY CANCER BIOLOGICS MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY CANCER BIOLOGICS MARKET SIZE, BY CONJUGATED MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY CANCER BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY CANCER BIOLOGICS MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
  • TABLE 181. UNITED ARAB EMIRATES CANCER BIOLOGICS MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES CANCER BIOLOGICS MARKET SIZE, BY CONJUGATED MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES CANCER BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES CANCER BIOLOGICS MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED KINGDOM CANCER BIOLOGICS MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM CANCER BIOLOGICS MARKET SIZE, BY CONJUGATED MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM CANCER BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM CANCER BIOLOGICS MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
  • TABLE 189. CANCER BIOLOGICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 190. CANCER BIOLOGICS MARKET, FPNV POSITIONING MATRIX, 2023